Filtered By:
Specialty: Pharmaceuticals
Education: Education
This page shows you your search results in order of date.
Order by Relevance | Date
Total 15 results found since Jan 2013.
Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Mayo Clinic in Arizona receives comprehensive stroke center certification
PHOENIX — Mayo Clinic Hospital in Phoenix announces that it has received certification from DNV as a comprehensive stroke center, reflecting the highest level of competence for treatment of serious stroke events. The DNV Comprehensive Stroke Center Certification is based on standards set forth by the Brai n Attack Coalition and the American Stroke Association, and affirms that the medical center addresses the full spectrum of stroke care – diagnosis, treatment, rehabilitation and education – and…
Source: Mayo Clinic Business News - May 24, 2022 Category: Pharmaceuticals Source Type: news
New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
TITUSVILLE, N.J., March 31, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an...
Source: Johnson and Johnson - March 31, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be age 65 or older...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Pulse Health ’s Pulse Engagement Cloud Platform Leverages SMS To...
The life science technology company drives significant consumer interaction and education around stroke awareness utilizing SMS engagement.(PRWeb January 27, 2020)Read the full story at https://www.prweb.com/releases/pulse_healths_pulse_engagement_cloud_platform_leverages_sms_to_increase_stroke_awareness/prweb16856728.htm
Source: PRWeb: Medical Pharmaceuticals - January 27, 2020 Category: Pharmaceuticals Source Type: news
At-Home Support Helps Stroke Patients Adjust After Hospitalization
WEDNESDAY, Aug. 7, 2019 -- Stroke patients discharged with a case manager and access to an educational website reported significantly greater improvements in physical health after three months compared with those who had traditional care, according...
Source: Drugs.com - Pharma News - August 7, 2019 Category: Pharmaceuticals Source Type: news
Pali Momi Medical Center opens simulation education lab
Pali Momi Medical Center opened its new simulation education lab on Thursday, the first of its kind in Central and West Oahu.
The Hawaii Pacific Health Center for Simulation and Education features high-tech manikins, equipment and classroom space to support education and training for the hospital’s health care professionals.
“As the only level III trauma center and primary stroke center in Central and West Oahu, P ali Momi Medical Center serves as a safety net for the residents on this side…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 27, 2018 Category: Pharmaceuticals Authors: Anna Hrushka Source Type: news
Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
FRIDAY, Oct. 12, 2018 -- A culturally tailored, skills-based educational intervention did not reduce systolic blood pressure at one year after stroke/transient ischemic attack, according to a study published online Oct. 8 in JAMA...
Source: Drugs.com - Pharma News - October 12, 2018 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk'
The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.
Source: World Pharma News - December 5, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education
Tammy Leitsinger to spearhead global physician education and peer-to-peer training for rapidly growing Trans Carotid Artery Revascularization (TCAR) procedure
SUNNYVALE, Calif., Oct. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Silk Road Medic... Devices, Neurology, Personnel Silk Road Medical, ENROUTE, TransCarotid Artery Revascularization, stroke
Source: HSMN NewsFeed - October 11, 2017 Category: Pharmaceuticals Source Type: news
Bayer and Ashfield Meetings & Events scoop ICE Award
The ICE Awards are the only events industry awards open exclusively to in-house corporate event planners. The award success celebrates the partnership between Bayer and Ashfield Meetings & Events. The relationship, now in its fifth year, started with the provision of venue sourcing services and has developed to provide full service solutions including developing communication objectives, creating content and designing different message delivery methods.
Judges cited that the submission was a standout entry in the category. They felt that the submission demonstrated a best practice example of how to approach agency rela...
Source: Ashfield Healthcare News - July 11, 2017 Category: Pharmaceuticals Authors: Ewan Jamieson Tags: Ashfield Source Type: news
Cynthia A. Bens
Vice President, Public PolicyCynthia Bens is the Vice President of Public Policy at the not-for-profit Alliance for Aging Research in Washington, D.C. In this capacity, Ms. Bens is responsible for guiding the organization’s federal policy work, representing the Alliance in multiple national coalitions, and directing all aspects of the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) and Aging in Motion (AIM) coalitions. Ms. Bens sits on the Alliance for a Stronger FDA Board of Directors and is a Founding Executive Committee Member of Friends of the National Institute on Aging (FoNIA). She has served on the...
Source: PHRMA - June 17, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news
If you could propose one idea to help improve health care delivery in the United States, what would it be?
Thumbnail: Tags: conversationsphrma conversationslarry hausnermyrl weinbergchris hansennancy brownContributors: 11621161115911631173Contributions: Read Larry Hausner's bio
Despite the rapid development of innovative technologies in the health care field, we have yet to discover a panacea that will easily transform our health care system into one that provides high-quality and cost-effective care. What we have discovered and come to agree on over the last decade is that our sick care system must be reconfigured to a health care system that emphasizes wellness and prevention. For that reason, I offer ...
Source: PHRMA - June 24, 2013 Category: Pharmaceuticals Authors: rlowe Source Type: news
